Compare Merck & Co., Inc. (MRK) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Atlassian Corporation PLC — how do they compare? Merck & Co., Inc. trades at $130.31 (market cap $323.00B), while Atlassian Corporation PLC trades at $153.5 (market cap $38.54B). The key difference: Merck & Co., Inc. is far larger — about 8.4× Atlassian Corporation PLC's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| MRK | TEAM | |
|---|---|---|
Market Cap | $323.00B | $38.54B |
Sector | Health | Technology |
52-Week High | $131.84 | $182.36 |
52-Week Low | $77.60 | $57.15 |
Enterprise Value | $369.77B | $38.53B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Atlassian Corporation (TEAM) surged 35.31% to $149.07 following a strong Q4 2026 earnings beat, with revenue up 28% year-over-year to $1.77 billion and cloud revenue accelerating to 31%. The stock is trading near its pivot point of $148, with bullish technical signals from moving averages but overbought RSI readings. Analysts maintain a strong buy consensus with a $161.93 price target, citing enterprise deal expansion and AI platform adoption as key growth drivers.
Outlook remains positive due to robust revenue growth and margin improvement, but risks include high valuation multiples (P/S 5.9, EV/EBITDA 178.27) and persistent net losses. Investors should weigh the company's cloud momentum against profitability challenges and macroeconomic uncertainty impacting software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
